Study Updates for Patients with a BRCA Mutation and Prior Breast Cancer скачать в хорошем качестве

Study Updates for Patients with a BRCA Mutation and Prior Breast Cancer

There were two important studies presented at SABCS 2024 looking at patients with a BRCA mutation and prior breast cancer. The first is a 6 year update on the OlympiA study which looks at using adjuvant olaparib (a PARP inhibitor) in patients with high risk HR+/HER2- or triple negative breast cancer. There is a continued benefit and significant improvement in invasive disease free survival (alive without invasive disease), distant disease free survival (alive without distant disease) and overall survival favoring the olaparib arm. I go over this in the video and also highlight the low rates of myelodysplastic syndrome/acute leukemia in both arms (0.4% in olaparib arm and 0.7% in placebo arm as MDS/AML is a rare but very serious PARP inhibitor toxicity) and that pregnancy outcomes after treatment were similar in both placebo and olaparib groups. The other study is an analysis of over 5000 patients from the BRCA BCY Collaboration of patients with a BRCA mutation who were diagnosed with breast cancer younger than age 40 and looking at impact of risk reducing bilateral mastectomy (RRM) or risk reducing salpingo-oophorectomy (RRSO). Bottom line: RRM and/or RRSO improved survival (RRM reduced rate of death by 35% and RRSO reduced rate of death by 42%) and reduced recurrence in this patient population. More in the video. A take away for me though is we also must focus on how to improve quality of life and long term health for patients who go through premature or early menopause (and this is not just limited to patients with a BRCA mutation). Would love to hear your thoughts! #brca #breastcancer #ovariancancer #sabcs24